AMAT vs. APH, SGM, MSI, MCP, BERI, INDI, STM, ATOM, INSG, and MIND
Should you be buying Amati AIM VCT stock or one of its competitors? The main competitors of Amati AIM VCT include Alliance Pharma (APH), Sigma Capital Group (SGM), MS INTERNATIONAL (MSI), Martin Currie Asia Unconstrand Trust (MCP), BlackRock Energy and Resources (BERI), Indus Gas (INDI), STM Group (STM), Atome (ATOM), Insig AI (INSG), and Mind Gym (MIND). These companies are all part of the "electronic equipment" industry.
Amati AIM VCT vs. Its Competitors
Alliance Pharma (LON:APH) and Amati AIM VCT (LON:AMAT) are both small-cap electronic equipment companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
Alliance Pharma currently has a consensus target price of GBX 6,250, indicating a potential upside of 9,559.97%. Given Alliance Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Alliance Pharma is more favorable than Amati AIM VCT.
In the previous week, Alliance Pharma's average media sentiment score of 0.00 equaled Amati AIM VCT'saverage media sentiment score.
Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.1%. Amati AIM VCT pays an annual dividend of GBX 5 per share and has a dividend yield of 8.1%. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend. Amati AIM VCT pays out -68.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amati AIM VCT is clearly the better dividend stock, given its higher yield and lower payout ratio.
66.3% of Alliance Pharma shares are owned by institutional investors. 12.0% of Alliance Pharma shares are owned by insiders. Comparatively, 0.5% of Amati AIM VCT shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Amati AIM VCT has lower revenue, but higher earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Amati AIM VCT, indicating that it is currently the more affordable of the two stocks.
Alliance Pharma has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Amati AIM VCT has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Amati AIM VCT has a net margin of 190.46% compared to Alliance Pharma's net margin of -18.34%. Amati AIM VCT's return on equity of -14.97% beat Alliance Pharma's return on equity.
Summary
Alliance Pharma beats Amati AIM VCT on 9 of the 15 factors compared between the two stocks.
Get Amati AIM VCT News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMAT and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amati AIM VCT Competitors List
Related Companies and Tools
This page (LON:AMAT) was last updated on 7/16/2025 by MarketBeat.com Staff
Free AMAT Stock Alerts